Opinion|Videos|January 23, 2025
HER2 Key Differences and Current Approaches to Biomarker Testing
Author(s)Misako Nagasaka, MD, PhD
Panelist discusses how HER2 testing evaluates protein overexpression, gene amplification, and mutations. Although breast and gastric cancers typically show overexpression/amplification, other tumors more commonly harbor mutations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the key differences between HER2 overexpression, amplification, and mutations across tumor types? How do these differences affect treatment selection?
- What is your current approach to biomarker testing for HER2 alterations across different tumor types?
Advertisement
Related to this article
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
2
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
3
Acting on a HER2 Result and Navigating Access to Therapy
4
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
5